GlobeNewswire

Invivoscribe Submits the LeukoStrat CDx FLT3 Mutation Assay to Support Daiichi Sankyo Submission for Quizartinib in Japan

Del

SAN DIEGO, Nov. 19, 2018 (GLOBE NEWSWIRE) -- In support of an ongoing partnership with Daiichi Sankyo, Invivoscribe is pleased to announce submission of the LeukoStrat® CDx FLT3 Mutation Assay to the PMDA (Pharmaceuticals and Medical Devices Agency) as the companion diagnostic for quizartinib, which follows Daiichi Sankyo’s PMDA application for quizartinib in Japan.

Invivoscribe developed the LeukoStrat CDx FLT3 Mutation Assay in partnership with Daiichi Sankyo as the companion diagnostic that bridges to the global phase 3 QuANTUM-R clinical trial (Europe, United States, Asia excluding Japan) in patients with relapsed/refractory FLT3 ITD AML. Together, QuANTUM-R clinical trial and open-label phase 2 study of quizartinib (Japan) support the Daiichi Sankyo New Drug Application (NDA) to Japan’s MHLW/PMDA for marketing approval of quizartinib for the treatment of adult patients with relapsed/refractory FLT3 ITD acute myeloid leukemia (AML).

This submission complements Invivoscribe’s prior regulatory approvals of this LeukoStrat CDx FLT3 Mutation Assay as an AML companion diagnostic in support of midostaurin for Novartis (United States and Europe), and gilteritinib fumarate for Astellas (Japan). Astellas and Invivoscribe have also submitted applications for the drug and device to the CDER and CDRH, respectively, in the United States.

This milestone helps to further establish the LeukoStrat CDx FLT3 Mutation Assay as the international standard for comprehensive FLT3 assessment for critically ill acute myeloid leukemia patients as this CDx is available worldwide and generates standardized signal ratios for both ITD and TKD mutations. These criteria are already resulting in more consistent stratification of patients which will help prescribing doctors identify personalized therapy options for their patients and accelerate new drug and therapy approvals by establishing more homogeneous patient populations for clinical trials.

Timing of this submission also reflects the efficiencies of Invivoscribe’s Streamlined CDx program, which provides pharmaceutical partners with integration of activities including CDx development, clinical trials support with rapid patient screening for enrollment, regulatory support and commercialization. Combining many of these activities can accelerate drug approvals as well as ensure rapid availability of the drugs to the appropriate patients following approvals.

“The LeukoStrat CDx FLT3 Mutation Assay Partial Change Approval Application submission and continuing Daiichi Sankyo partnership represent significant milestones for our company. We continue to welcome opportunities to partner with global pharmaceutical companies interested in developing and commercializing companion diagnostics, whether for hematologic disease or solid tumors,” said Jeffrey Miller, Invivoscribe’s CSO and CEO. “Invivoscribe remains focused on improving the quality of healthcare worldwide by providing high quality, standardized reagents, tests, and bioinformatics tools to advance the field of precision medicine.”

About the Invivoscribe LeukoStrat CDx FLT3 Mutation Assay

The LeukoStrat CDx FLT3 Mutation Assay is a PCR-based, in vitro diagnostic test designed to detect internal tandem duplication (ITD) mutations and tyrosine kinase domain (TKD) mutations D835 and I836 in the FLT3 gene in genomic DNA extracted from mononuclear cells obtained from peripheral blood or bone marrow aspirates of patients diagnosed with acute myelogenous leukemia. This globally standardized test includes software that interprets data, generates mutant/wildtype signal ratios for ITD and TKD mutations, and predicts response to both gilteritinib fumarate and midostaurin. This extensively validated assay helps standardize the detection of genetic mutations in the FLT3 gene as one of the most important driver mutations in Acute Myeloid Leukemia (AML). In serving as the companion diagnostic to the Daiichi Sankyo sponsored clinical trials, this test reports out FLT3 ITD mutations alone.

The LeukoStrat test is currently available as a test menu service through the Invivoscribe subsidiaries, LabPMM LLC (San Diego, CA, US), LabPMM GmbH (Martinsried, Germany) and LabPMM GK (Kawasaki City, Japan). LeukoStrat CDx FLT3 Mutation Assay kits are currently distributed in Europe. Distribution of kits in Japan, United States, and China are planned.

About Invivoscribe

Invivoscribe is a privately held biotechnology company dedicated to Improving Lives with Precision Diagnostics. For nearly twenty-five years, Invivoscribe has improved the quality of healthcare worldwide by providing high quality, standardized reagents, tests, and bioinformatics tools to advance the field of precision medicine. Invivoscribe has a successful track record of partnerships with global pharmaceutical companies interested in developing and commercializing companion diagnostics, and provides expertise in both regulatory and laboratory services. Providing distributable kits, as well as clinical trial services through its globally located clinical lab subsidiaries (LabPMM), Invivoscribe is an ideal partner from diagnostic development through clinical trials and regulatory submissions. For additional information please contact Invivoscribe at support@invivoscribe.com or visit www.invivoscribe.com.

 

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

RedAwning Opens Up New Office in Palma de Mallorca, Spain To Offer Industry-Leading Distribution, Marketing + Reservations Services to European Property Managers20.2.2019 02:30:00Pressemelding

New Jetstream Team Office To Support RedAwning Group’s Expansion in Europe and Provide Comprehensive Support For International Clients Emeryville, California, Feb. 19, 2019 (GLOBE NEWSWIRE) -- RedAwning, the world’s largest collection of vacation properties, today announced that it has opened up an office in ParcBit, Palma de Mallorca, Spain to service the RedAwning Group’s growing portfolio of international vacation property managers and to offer RedAwning’s industry-leading distribution, marketing and reservation solutions to managers of alternative accommodations throughout Europe. RedAwning is a single point of entry for managers of single vacation homes and multi-unit boutique hotels, resorts, apart-hotels and corporate apartments to access the widest online travel network in the world, including Booking.com, Expedia, Airbnb, and HomeAway/VRBO, as well as a major travel metasearch sites including trivago, Holidu, HomeToGo and TripAdvisor. RedAwning is also integrated with Google H

STORDIS Joins Open Compute Project as Platinum Member and Announces OCP Global Summit Sponsorship20.2.2019 00:02:00Pressemelding

Austin, TX, Feb. 19, 2019 (GLOBE NEWSWIRE) -- The Open Compute Project Foundation (OCP) announced today that STORDIS, a full-service provider in the field of Open Networking that offers consultancy, system integration, professional support and software development services, has joined as a Platinum member. OCP was initiated in 2011 with a mission to apply the benefits of open source to hardware and rapidly increase the pace of innovation in, near and around the data center and beyond. Since then, OCP has been consistently innovating around open-source contributions, with 200 member companies and thousands of technology leaders and engineers worldwide. STORDIS, an official sponsor of the OCP Global Summit, has built a great reputation and a leading industry network since it was founded in 2007. The company, which is completely dedicated to the idea of Open Networking, counts as one of Europe’s leaders in this emerging technology and is especially known for its knowledge on the P4 progra

Dubai Airports partners with XDubai for one-of-a-kind stunt embodying Dubai’s ambitious spirit19.2.2019 15:46:00Pressemelding

Stunt showcases refreshed DXB brand’s vision of pushing boundaries and creating new experiences DUBAI, United Arab Emirates, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Dubai Airports has partnered with action sports brand XDubai to deliver an incredible one-of-a-kind stunt by Emirati athlete and skydiver Mohammed Baker, as part of the new DXB brand which aims to position the world’s busiest international airport as a major destination for culture, hospitality, and entertainment. The stunning showcase, captured in a short film released by both Dubai Airports and XDubai, just following the refreshed brand reveal recently, captures what is believed to be the world’s longest skydive swoop under a fixed structure. As showcased in the video, skydiver Mohammed Baker jumps out of a helicopter with a parachute emblazoned with the new DXB brand, gliding through the Dubai sky before performing one of the world’s longest skydive swoops - measuring 112m - under the Sheikh Zayed Road bridge. With Downtown Du

New PubMatic Research Finds Mobile In-App Monetization Spurred by Video and Header Bidding, Though Challenges Remain19.2.2019 15:00:00Pressemelding

Company releases Q4 2018 QMI report, highlighting key trends in mobile advertising growth REDWOOD CITY, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- PubMatic, the publisher-focused sell-side platform (SSP) for an open digital media future, today released its fourth Quarterly Mobile Index (QMI) of 2018. The report highlights key trends influencing mobile advertising growth, allowing publishers and advertisers to make smarter decisions around their programmatic strategies. Advertisers are increasingly attracted to the enhanced targeting and increased customer engagement of mobile in-app, with many buyers opting for programmatic transaction methods for this inventory (Forrester Consulting). PubMatic’s Q4 2018 QMI Report found that in-app video ad spend was up over 200 percent year-over-year in 2018 as buyers embrace in-stream opportunities. Header bidding technology is also beginning to take hold within the in-app environment, with impression volumes growing more than 300X year-over-year in

Canada Rare Earth Reinvigorates a South American Rare Earth Mine and Processing Opportunity19.2.2019 14:45:00Pressemelding

VANCOUVER, British Columbia, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Canada Rare Earth Corp. (“Canada Rare Earth” or the “Company”) (TSX.V: LL) is pleased to announce that it has re-established discussions and momentum with the owners (the “Owners”) of an advanced prospective rare earth property situated in South America (the “Property”). The recent dialogue has resulted in an agreement outlined in a non-binding letter of intent (the “2019 LOI”) which is significantly different from the original letter of intent announced on October 17, 2017 (the “2017 LOI”). The 2019 LOI is simpler in many regards. For example, under the 2019 LOI Canada Rare Earth will purchase the rare earth concentrate for either sale or further processing onsite, whereas the 2017 LOI provided for more of a joint venture collaboration with joint management and cross ownership of the prospective mine and processing facilities. The 2019 LOI and the 2017 LOI are consistent in that: The Owners will prepare and transport a 50-

Cloudian Solves Backup Challenges for European Managed Services Provider19.2.2019 14:00:00Pressemelding

Provides Limitlessly Scalable, Cost-effective Storage Foundation for Data Protection SAN MATEO, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Cloudian today announced that Systemec, a managed services provider specializing in health care and logistics in the Netherlands and Germany, has deployed Cloudian’s HyperStore object storage platform to address the backup challenges of growing data volumes. Cloudian enables Systemec to protect data from multiple applications, prevent the scheduling problems it previously faced and achieve increased cost efficiency. Continued Data Growth Threatens to Overwhelm Backup Windows Founded in 2007, Systemec runs two data centers in The Netherlands and one in Germany under a unique cross-border strategy that supports more than 500 customers. As the amount of data the company manages rapidly increased, Systemec realized it needed a cost-effective solution to store and secure customer data. “This growth raised concerns about accommodating the future data volum